Cancer vaccine strategies get bigger and better.

Many anti-tumor vaccines have failed in recent clinical trials because they included the wrong patients and the wrong immune adjuvants ? and little was learned because the anti-tumor immune response was not carefully monitored. A new tumor vaccine for lymphoma sets the stage for how future trials should be carried out (pages 1171?1177). [ABSTRACT FROM AUTHOR]